Ascites Market

ID: MRFR/MED/1377-CR
130 Pages
Nidhi Mandole
Last Updated: March 26, 2026
Ascites Market Research Report Information by Types (Transudative Ascites and Exudate Ascites), Diagnosis (Ultrasound, CT Scan, Laparoscopy and Angiography), Treatment (Surgeries), End Users (Hospitals & Clinics, Ambulatory Surgical Center and Diagnostic Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2035
Ascites Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.44%
2024 Market Size$ 1.37 Billion
2025 Market Size$ 1.46 Billion
2035 Market Size$ 2.73 Billion
Key Players
Bristol-Myers Squibb
Roche
Novartis
Gilead Sciences
Merck & Co.
Amgen
Trends
  • Rising Incidence of Liver Diseases
  • Advancements in Treatment Modalities
  • Shift Towards Personalized Medicine
Opportunities
  • Growing Awareness and Education
  • Increasing Prevalence of Ascites
  • Expansion of Healthcare Infrastructure
Summary Table of Contents Segmentation Methodology Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type (USD Billion)
      1. 4.1.1 Transudative Ascites
      2. 4.1.2 Exudate Ascites
    2. 4.2 Healthcare, BY Diagnosis (USD Billion)
      1. 4.2.1 Ultrasound
      2. 4.2.2 CT scan
      3. 4.2.3 MRI
      4. 4.2.4 Blood test
      5. 4.2.5 Laparoscopy
      6. 4.2.6 Angiography
    3. 4.3 Healthcare, BY Treatment (USD Billion)
      1. 4.3.1 Medication
      2. 4.3.2 Paracentesis
      3. 4.3.3 Surgery
    4. 4.4 Healthcare, BY Route of Administration (USD Billion)
      1. 4.4.1 Oral
      2. 4.4.2 Parenteral
      3. 4.4.3 Others
    5. 4.5 Healthcare, BY End-users (USD Billion)
      1. 4.5.1 Hospitals
      2. 4.5.2 Specialty Clinics
      3. 4.5.3 Home Care
    6. 4.6 Healthcare, BY Allotment Channel (USD Billion)
      1. 4.6.1 Hospital Pharmacies
      2. 4.6.2 Retail Pharmacies
      3. 4.6.3 Online Pharmacies
    7. 4.7 Healthcare, BY Region (USD Billion)
      1. 4.7.1 North America
        1. 4.7.1.1 US
        2. 4.7.1.2 Canada
      2. 4.7.2 Europe
        1. 4.7.2.1 Germany
        2. 4.7.2.2 UK
        3. 4.7.2.3 France
        4. 4.7.2.4 Russia
        5. 4.7.2.5 Italy
        6. 4.7.2.6 Spain
        7. 4.7.2.7 Rest of Europe
      3. 4.7.3 APAC
        1. 4.7.3.1 China
        2. 4.7.3.2 India
        3. 4.7.3.3 Japan
        4. 4.7.3.4 South Korea
        5. 4.7.3.5 Malaysia
        6. 4.7.3.6 Thailand
        7. 4.7.3.7 Indonesia
        8. 4.7.3.8 Rest of APAC
      4. 4.7.4 South America
        1. 4.7.4.1 Brazil
        2. 4.7.4.2 Mexico
        3. 4.7.4.3 Argentina
        4. 4.7.4.4 Rest of South America
      5. 4.7.5 MEA
        1. 4.7.5.1 GCC Countries
        2. 4.7.5.2 South Africa
        3. 4.7.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Gilead Sciences (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Johnson & Johnson (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AbbVie (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Sanofi (FR)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TYPE
    4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS
    5. 6.5 US MARKET ANALYSIS BY TREATMENT
    6. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    7. 6.7 US MARKET ANALYSIS BY END-USERS
    8. 6.8 US MARKET ANALYSIS BY ALLOTMENT CHANNEL
    9. 6.9 CANADA MARKET ANALYSIS BY TYPE
    10. 6.10 CANADA MARKET ANALYSIS BY DIAGNOSIS
    11. 6.11 CANADA MARKET ANALYSIS BY TREATMENT
    12. 6.12 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    13. 6.13 CANADA MARKET ANALYSIS BY END-USERS
    14. 6.14 CANADA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    15. 6.15 EUROPE MARKET ANALYSIS
    16. 6.16 GERMANY MARKET ANALYSIS BY TYPE
    17. 6.17 GERMANY MARKET ANALYSIS BY DIAGNOSIS
    18. 6.18 GERMANY MARKET ANALYSIS BY TREATMENT
    19. 6.19 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    20. 6.20 GERMANY MARKET ANALYSIS BY END-USERS
    21. 6.21 GERMANY MARKET ANALYSIS BY ALLOTMENT CHANNEL
    22. 6.22 UK MARKET ANALYSIS BY TYPE
    23. 6.23 UK MARKET ANALYSIS BY DIAGNOSIS
    24. 6.24 UK MARKET ANALYSIS BY TREATMENT
    25. 6.25 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    26. 6.26 UK MARKET ANALYSIS BY END-USERS
    27. 6.27 UK MARKET ANALYSIS BY ALLOTMENT CHANNEL
    28. 6.28 FRANCE MARKET ANALYSIS BY TYPE
    29. 6.29 FRANCE MARKET ANALYSIS BY DIAGNOSIS
    30. 6.30 FRANCE MARKET ANALYSIS BY TREATMENT
    31. 6.31 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    32. 6.32 FRANCE MARKET ANALYSIS BY END-USERS
    33. 6.33 FRANCE MARKET ANALYSIS BY ALLOTMENT CHANNEL
    34. 6.34 RUSSIA MARKET ANALYSIS BY TYPE
    35. 6.35 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
    36. 6.36 RUSSIA MARKET ANALYSIS BY TREATMENT
    37. 6.37 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    38. 6.38 RUSSIA MARKET ANALYSIS BY END-USERS
    39. 6.39 RUSSIA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    40. 6.40 ITALY MARKET ANALYSIS BY TYPE
    41. 6.41 ITALY MARKET ANALYSIS BY DIAGNOSIS
    42. 6.42 ITALY MARKET ANALYSIS BY TREATMENT
    43. 6.43 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    44. 6.44 ITALY MARKET ANALYSIS BY END-USERS
    45. 6.45 ITALY MARKET ANALYSIS BY ALLOTMENT CHANNEL
    46. 6.46 SPAIN MARKET ANALYSIS BY TYPE
    47. 6.47 SPAIN MARKET ANALYSIS BY DIAGNOSIS
    48. 6.48 SPAIN MARKET ANALYSIS BY TREATMENT
    49. 6.49 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    50. 6.50 SPAIN MARKET ANALYSIS BY END-USERS
    51. 6.51 SPAIN MARKET ANALYSIS BY ALLOTMENT CHANNEL
    52. 6.52 REST OF EUROPE MARKET ANALYSIS BY TYPE
    53. 6.53 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
    54. 6.54 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
    55. 6.55 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    56. 6.56 REST OF EUROPE MARKET ANALYSIS BY END-USERS
    57. 6.57 REST OF EUROPE MARKET ANALYSIS BY ALLOTMENT CHANNEL
    58. 6.58 APAC MARKET ANALYSIS
    59. 6.59 CHINA MARKET ANALYSIS BY TYPE
    60. 6.60 CHINA MARKET ANALYSIS BY DIAGNOSIS
    61. 6.61 CHINA MARKET ANALYSIS BY TREATMENT
    62. 6.62 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    63. 6.63 CHINA MARKET ANALYSIS BY END-USERS
    64. 6.64 CHINA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    65. 6.65 INDIA MARKET ANALYSIS BY TYPE
    66. 6.66 INDIA MARKET ANALYSIS BY DIAGNOSIS
    67. 6.67 INDIA MARKET ANALYSIS BY TREATMENT
    68. 6.68 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    69. 6.69 INDIA MARKET ANALYSIS BY END-USERS
    70. 6.70 INDIA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    71. 6.71 JAPAN MARKET ANALYSIS BY TYPE
    72. 6.72 JAPAN MARKET ANALYSIS BY DIAGNOSIS
    73. 6.73 JAPAN MARKET ANALYSIS BY TREATMENT
    74. 6.74 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    75. 6.75 JAPAN MARKET ANALYSIS BY END-USERS
    76. 6.76 JAPAN MARKET ANALYSIS BY ALLOTMENT CHANNEL
    77. 6.77 SOUTH KOREA MARKET ANALYSIS BY TYPE
    78. 6.78 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
    79. 6.79 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
    80. 6.80 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    81. 6.81 SOUTH KOREA MARKET ANALYSIS BY END-USERS
    82. 6.82 SOUTH KOREA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    83. 6.83 MALAYSIA MARKET ANALYSIS BY TYPE
    84. 6.84 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
    85. 6.85 MALAYSIA MARKET ANALYSIS BY TREATMENT
    86. 6.86 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    87. 6.87 MALAYSIA MARKET ANALYSIS BY END-USERS
    88. 6.88 MALAYSIA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    89. 6.89 THAILAND MARKET ANALYSIS BY TYPE
    90. 6.90 THAILAND MARKET ANALYSIS BY DIAGNOSIS
    91. 6.91 THAILAND MARKET ANALYSIS BY TREATMENT
    92. 6.92 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    93. 6.93 THAILAND MARKET ANALYSIS BY END-USERS
    94. 6.94 THAILAND MARKET ANALYSIS BY ALLOTMENT CHANNEL
    95. 6.95 INDONESIA MARKET ANALYSIS BY TYPE
    96. 6.96 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
    97. 6.97 INDONESIA MARKET ANALYSIS BY TREATMENT
    98. 6.98 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    99. 6.99 INDONESIA MARKET ANALYSIS BY END-USERS
    100. 6.100 INDONESIA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    101. 6.101 REST OF APAC MARKET ANALYSIS BY TYPE
    102. 6.102 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
    103. 6.103 REST OF APAC MARKET ANALYSIS BY TREATMENT
    104. 6.104 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    105. 6.105 REST OF APAC MARKET ANALYSIS BY END-USERS
    106. 6.106 REST OF APAC MARKET ANALYSIS BY ALLOTMENT CHANNEL
    107. 6.107 SOUTH AMERICA MARKET ANALYSIS
    108. 6.108 BRAZIL MARKET ANALYSIS BY TYPE
    109. 6.109 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
    110. 6.110 BRAZIL MARKET ANALYSIS BY TREATMENT
    111. 6.111 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    112. 6.112 BRAZIL MARKET ANALYSIS BY END-USERS
    113. 6.113 BRAZIL MARKET ANALYSIS BY ALLOTMENT CHANNEL
    114. 6.114 MEXICO MARKET ANALYSIS BY TYPE
    115. 6.115 MEXICO MARKET ANALYSIS BY DIAGNOSIS
    116. 6.116 MEXICO MARKET ANALYSIS BY TREATMENT
    117. 6.117 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    118. 6.118 MEXICO MARKET ANALYSIS BY END-USERS
    119. 6.119 MEXICO MARKET ANALYSIS BY ALLOTMENT CHANNEL
    120. 6.120 ARGENTINA MARKET ANALYSIS BY TYPE
    121. 6.121 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
    122. 6.122 ARGENTINA MARKET ANALYSIS BY TREATMENT
    123. 6.123 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    124. 6.124 ARGENTINA MARKET ANALYSIS BY END-USERS
    125. 6.125 ARGENTINA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    126. 6.126 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    127. 6.127 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
    128. 6.128 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
    129. 6.129 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    130. 6.130 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USERS
    131. 6.131 REST OF SOUTH AMERICA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    132. 6.132 MEA MARKET ANALYSIS
    133. 6.133 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    134. 6.134 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
    135. 6.135 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
    136. 6.136 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    137. 6.137 GCC COUNTRIES MARKET ANALYSIS BY END-USERS
    138. 6.138 GCC COUNTRIES MARKET ANALYSIS BY ALLOTMENT CHANNEL
    139. 6.139 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    140. 6.140 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
    141. 6.141 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
    142. 6.142 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    143. 6.143 SOUTH AFRICA MARKET ANALYSIS BY END-USERS
    144. 6.144 SOUTH AFRICA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    145. 6.145 REST OF MEA MARKET ANALYSIS BY TYPE
    146. 6.146 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
    147. 6.147 REST OF MEA MARKET ANALYSIS BY TREATMENT
    148. 6.148 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    149. 6.149 REST OF MEA MARKET ANALYSIS BY END-USERS
    150. 6.150 REST OF MEA MARKET ANALYSIS BY ALLOTMENT CHANNEL
    151. 6.151 KEY BUYING CRITERIA OF HEALTHCARE
    152. 6.152 RESEARCH PROCESS OF MRFR
    153. 6.153 DRO ANALYSIS OF HEALTHCARE
    154. 6.154 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    155. 6.155 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    156. 6.156 SUPPLY / VALUE CHAIN: HEALTHCARE
    157. 6.157 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    158. 6.158 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    159. 6.159 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
    160. 6.160 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
    161. 6.161 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
    162. 6.162 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
    163. 6.163 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    164. 6.164 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    165. 6.165 HEALTHCARE, BY END-USERS, 2024 (% SHARE)
    166. 6.166 HEALTHCARE, BY END-USERS, 2024 TO 2035 (USD Billion)
    167. 6.167 HEALTHCARE, BY ALLOTMENT CHANNEL, 2024 (% SHARE)
    168. 6.168 HEALTHCARE, BY ALLOTMENT CHANNEL, 2024 TO 2035 (USD Billion)
    169. 6.169 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.2.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.2.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.3.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.3.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.3.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.4.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.4.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.4.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.5.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.5.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.5.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.6.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.6.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.6.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.7.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.7.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.7.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.8.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.8.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.8.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.9.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.9.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.9.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.10.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.10.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.10.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.11.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.11.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.11.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.12.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.12.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.12.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.13.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.13.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.13.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.14.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.14.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.14.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.15.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.15.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.15.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.16.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.16.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.16.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.17.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.17.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.17.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.18.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.18.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.18.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.19.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.19.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.19.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.20.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.20.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.20.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.21.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.21.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.21.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.22.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.22.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.22.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.23.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.23.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.23.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.24.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.24.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.24.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.25.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.25.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.25.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.26.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.26.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.26.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.27.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.27.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.27.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.28.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.28.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.28.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.29.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.29.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.29.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.30.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.30.5 BY END-USERS, 2025-2035 (USD Billion)
      6. 7.30.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Ascites Market Segmentation

Ascites Market By Type (USD Billion, 2025-2035)

  • Transudative Ascites
  • Exudate Ascites

Ascites Market By Diagnosis (USD Billion, 2025-2035)

  • Ultrasound
  • CT scan
  • MRI
  • Blood test
  • Laparoscopy
  • Angiography

Ascites Market By Treatment (USD Billion, 2025-2035)

  • Medication
  • Paracentesis
  • Surgery

Ascites Market By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Parenteral
  • Others

Ascites Market By End-users (USD Billion, 2025-2035)

  • Hospitals
  • Specialty Clinics
  • Home Care

Ascites Market By Allotment Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.